Unmet Needs in Allogeneic Transplant and Precision-T Data Discussion

The faculty open by framing the current state of allogeneic stem cell transplantation, describing an era in which a suitable donor can be identified for the vast majority of patients and in which advances in upfront treatment of hematologic malignancies are bringing more patients into remission and therefore into transplant eligibility. Against that backdrop, the central unmet need is defined as improving disease control without paying an unacceptably high price in treatment-related morbidity. Relapse remains the leading cause of treatment failure, while graft-vs-host disease (GVHD), infection, organ toxicity, and prolonged immunosuppression continue to constrain long-term survivorship and quality of life. The panel frames the core challenge as reducing GVHD without increasing the risk of severe infection or relapse. Discussion then turns to the FDA approval of allogeneic regulatory T-cell immunotherapy with hematopoietic stem and progenitor cells (HSPCs) and T cells, known as Orca-T, and to the randomized phase 3 Precision-T trial. Orca-T is described as a precision-engineered, donor-derived cellular immunotherapy delivering 3 defined components rather than an unmanipulated peripheral blood graft, with HSPCs and purified regulatory T cells infused on day 0 to establish an immunologic environment that suppresses excessive alloreactivity, followed by conventional T cells on day plus 2 to support immune reconstitution. Precision-T randomized 187 patients undergoing matched related or matched unrelated myeloablative conditioning transplant to Orca-T followed by single-agent tacrolimus or a conventional peripheral blood graft followed by tacrolimus and methotrexate. Survival free of moderate to severe chronic GVHD was 78% with Orca-T vs 38% with conventional transplant, nonrelapse mortality was 3%, and no primary graft failures were observed.